CD8A and neoplasm: Like Treg cells, TAMs can also inhibit tumor-associated antigens (TAA)-specific CD8+ T cell activation, which are capable of engaging tumor cells in an antigen-specific manner and drive antitumor immunity by secreting effector cytokines [35,36,37,38].